Skip to main content

Table 3 Non randomized clinical trials of HCC treatment with SA monotherapy

From: The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets

Publication Type of study Number of enrolled patients and controls Type of Cancer SA used for treatment Response to treatment-outcome
   Patients Controls    
Dimitroulopoulos 2002[211] NRCT 15* 13# Advanced HCC OCT LAR (20 to 30 mg/28d) ↑S, ↑QoL
Gill 2005[212] NRCT 22* 20# Advanced HCC OCT LAR (20 mg/28d) ↑S, ↑QoL, ↓AFP, PR
Samonakis 2002[213] NRCT 32* 27# Advanced HCC NS ↑S, ↑QoL,
Plentz 2005[214] NRCT 41* 33▪ Advanced HCC OCT LAR (30 mg/28d) =S
Schoniger-Hekele 2009[215] NRCT 25* 39† Advanced HCC OCT LAR (30 mg/28d) ↑S
   or 17▪     
   or 17▫     
Slijkhuis 2005[216] NRCT 30* - Advanced HCC OCT LAR (30 mg/28d) SD
  1. NRCT, Non randomized clinical trial.
  2. AFP, Alpha fetoprotein.
  3. S, Survival.
  4. TACE, Transarterial chemoembolization.
  5. PR, Partial response.
  6. SD, Stable disease.
  7. NS, Not specified.
  8. QoL, Quality of life.
  9. *: treated patients.
  10. #: untreated patients.
  11. ▪: TACE treatment.
  12. ▫: multimodal therapy.
  13. †: palliative.